product's FDA-approved prescribing information (or package insert), AND member meets Epkinly (epcoritamab-bysp ) [package insert]. Genmab US
Epkinly (epcoritamab-bysp) is a T-cell engaging bispecific Epkinly [package insert]. Plainsboro (NJ): Genmab US, Inc.; 2024
Epkinly Prescribing Information. Package insert / product label Generic name: epcoritamab-bysp Dosage form: injection, solution Drug class: Bispecific T-cell engagers (BiTE) J Code (medical billing code): J9321 (0.16 mg, injection)
Oncology Drug Reference Sheet: Epcoritamab-Bysp Black box warnings: The package insert has a boxed warning for the risk of CRS and immune
Epcoritamab [package insert]. North Chicago, IL: AbbVie, Inc. and Plainsboro, NJ: Genmab US, Inc.: May 2024. HEMATOLOGIC MALIGNANCIES Blue Bar. Diffuse Large
Black box warnings: The package insert has a boxed warning for the risk of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS). Other warnings: Epcoritamab-bysp may cause fetal harm when administered to a pregnant individual.
Epcoritamab-bysp (Epkinly Specific instructions on what to do if the dose is delayed during ramp-up can be found in the package insert.
Package insert. Hospira; 2024. 19. Cefazolin. Package insert. GSK; 2024. 20. Ceftriaxone. Package insert. Sandoz; 2024. 21. Daptomycin. Package insert
On J, The Food and Drug Administration approved epcoritamab-bysp (e.g, Epkinly) Epkinly [package insert]. Plainsboro, NJ; Genmab
I would like to know more about this package. ^.^